Objective: To evaluate immunogenicity and reactogenicity of primary vaccination with
reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) or dTpa-inactivated …

Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …

Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents
or adults and the need for pertussis booster vaccination beyond childhood is increasingly …

Introduction The immunogenicity and safety of one dose of Tdap-IPV (tetanus, diphtheria,
acellular pertussis and inactivated poliomyelitis vaccine) and two doses of Td-IPV (tetanus …

High rates of pertussis disease in adolescents suggest that additional boosting against
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …

Reduced-antigen-content pertussis vaccines designed initially for booster vaccination of
adolescents and adults can also be used to vaccinate pre-school age children. Combination …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …

Background. The changing epidemiology of pertussis in France has emphasized the need
for booster vaccinations in adolescents. Although not previously recommended because of …

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …